April 2014 Issue of MMM
APRIL 2014 issue
Content marketing is no mystery. It's just the art of sharing good stories
Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.
Given the adoption of in-app video and gaming, forward-looking pharma marketers are experimenting with so-called smart DTC on small screens—and the skeptics might not be ...
Here's a countdown of 10 risk-taking ads—five that our industry experts thought truly succeeded, followed by five that might have done better. It's our shout-out ...
For rare diseases and orphan products, the future looks promising, but as Peter Saltonstall finds, significant research, educational and policy challenges remain. A view from ...
Sales force success in the new world of prescribing takes technology. Harris Kaplan and Ann Mayer say substituting e-sampling for rep time could be a ...
Brian Goff, Global franchise head for hemophilia, Baxter
With generics firms taking aim at high-flying blockbusters, Big Pharma stalwarts in the asthma and COPD market are pinning their hopes for the future on ...
Pharmaceutical companies must provide robust marketing support for their clinical trials
The pros and cons of e-cigarettes
Allowing copies of branded biologic medicines to share the original drug's non-proprietary name will have little or no consequence for patient safety, most stakeholders and ...
Kynamro's slow start, coupled with competition, has prompted Sanofi to add sales reps.
Endo Pharmaceuticals became the latest drugmaker to ink an off-label marketing settlement, paying $192.7 million to resolve charges it promoted pain patch Lidoderm for unapproved ...
News on Physicians Interactive, National Association of Boards of Pharmacy and Roche
Med Ed Report
The approach of new transparency rules, coupled with patent losses and industry's shift to specialty meds, has contributed to a big drop in the amount ...
There is an "overwhelming need" among HCPs for greater awareness, training and education on the diagnosis and available treatment options for rare diseases, researchers suggest.
The FDA's proposed upgrade to its off-label distribution guidelines has some new features, but experts say it is unclear if this means more dollars will ...
The newly titled Nurse Practitioner Perspective rolls out this month, keeping pace with an educational shift in the nursing field.
News on MedCAREERS Group Inc., F1000 and the American Academy of Orthopaedic Surgeons
Research shows HCPs bounce from site to site, so rep networks seem to offer both one-stop info shopping and industry contact. But do they provide ...
The FDA's bad-ad unit took a drugmaker to task for what it calls a misleading Facebook page. History shows the social media surveillance should take ...
A report of over 270,000 US medical sites signals that EHR adoption is no longer a luxury reserved for hospitals and health systems.
News on the Journal of the American Medical Association, the National Multiple Sclerosis Society and FDA
Pfizer's consumer website for Advil in South Korea offers a strange appeal to women who experience menstrual pain.
The publisher aims to bring patient stories to life through long-form multimedia narratives.
AZ has taught us a lot about acid reflux disease over the years, but the latest Nexium campaign looks like the creative team simply gave ...
Merck has broadened its analytics approach to include team-ups with a slate of organizations at the intersection of Big Data and health IT.
Researchers have developed and tested a checklist that aims to evaluate comparative effectiveness research and distinguish real-world studies that are good enough for decision-making about ...
Draftfcb Healthcare has rebranded to FCB Health, and has also acquired UK healthcare agency Halesway, effective immediately, the agency announced today
LEO Pharma has inked an extension for its public relations contract with Edelman's Frankfurt, Germany office, according to news outlet PMLiVE.
News on N.S. Bienstock, Ogilvy CommonHealth, AbelsonTaylor and TGaS
The more clarity that FDA provides, the more confident companies can be in their medical communications
US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's ...
FDA's Office of Prescription Drug Promotion (OPDP) plans to research the effects that could follow changing the risk information the agency requires to be included ...
The question should be: How do you simplify and identify the moments that mean the most to customers?
Prescribing decisions have become tied to potential therapeutic benefits and the total "Patient Experience"
In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience
Maggie Helmig, EVP, global brand lead, Ogilvy CommonHealth
At Work With
Adam Scott Roberts, Senior Vice President, Group Media Director, Communications Media Inc.
Promotions and hires for manufacturers and agencies
There's no cure. But the good news is that prophylaxis is possible.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.